TR201816574T4 - Anti-ılt7 antikoru. - Google Patents

Anti-ılt7 antikoru. Download PDF

Info

Publication number
TR201816574T4
TR201816574T4 TR2018/16574T TR201816574T TR201816574T4 TR 201816574 T4 TR201816574 T4 TR 201816574T4 TR 2018/16574 T TR2018/16574 T TR 2018/16574T TR 201816574 T TR201816574 T TR 201816574T TR 201816574 T4 TR201816574 T4 TR 201816574T4
Authority
TR
Turkey
Prior art keywords
antibody
ilt7
pro
cells
lou
Prior art date
Application number
TR2018/16574T
Other languages
English (en)
Turkish (tr)
Inventor
Kamogawa Yumiko
Cho Minkwon
Arai Naoko
Ishida Koji
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of TR201816574T4 publication Critical patent/TR201816574T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
TR2018/16574T 2005-12-20 2006-12-20 Anti-ılt7 antikoru. TR201816574T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20

Publications (1)

Publication Number Publication Date
TR201816574T4 true TR201816574T4 (tr) 2018-11-21

Family

ID=38188642

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/16574T TR201816574T4 (tr) 2005-12-20 2006-12-20 Anti-ılt7 antikoru.

Country Status (29)

Country Link
US (6) US8084585B2 (OSRAM)
EP (4) EP3441403A1 (OSRAM)
JP (2) JP5020828B2 (OSRAM)
KR (3) KR101585532B1 (OSRAM)
CN (5) CN105111311B (OSRAM)
AU (1) AU2006328470B2 (OSRAM)
BR (1) BRPI0620141B1 (OSRAM)
CA (2) CA2634116C (OSRAM)
CY (3) CY1114227T1 (OSRAM)
DK (3) DK1964852T3 (OSRAM)
ES (3) ES2526079T3 (OSRAM)
HK (1) HK1218126A1 (OSRAM)
HR (2) HRP20130494T1 (OSRAM)
HU (1) HUE039865T2 (OSRAM)
IL (1) IL192266A (OSRAM)
LT (1) LT2913343T (OSRAM)
ME (1) ME02111B (OSRAM)
MX (1) MX2008007682A (OSRAM)
NZ (3) NZ616992A (OSRAM)
PL (3) PL2532681T3 (OSRAM)
PT (3) PT2913343T (OSRAM)
RS (2) RS52860B (OSRAM)
RU (2) RU2456298C2 (OSRAM)
SG (2) SG10201602095PA (OSRAM)
SI (3) SI1964852T1 (OSRAM)
TR (1) TR201816574T4 (OSRAM)
UA (1) UA97946C2 (OSRAM)
WO (1) WO2007072866A1 (OSRAM)
ZA (1) ZA200805850B (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
WO2011063237A2 (en) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
SMT201700139T1 (it) 2010-02-24 2017-05-08 Immunogen Inc Immunoconiugati contro il recettore 1 del folato e relativi usi
EP2563393B1 (en) * 2010-04-26 2016-06-08 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
PT2828284T (pt) 2012-03-20 2019-06-17 Biogen Ma Inc Jcv neutralizando anticorpos
CA2867910C (en) 2012-03-20 2023-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
ES2848052T3 (es) * 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
SG11201601037YA (en) 2013-08-30 2016-03-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
KR20160099083A (ko) * 2013-12-24 2016-08-19 아스테라스 세이야쿠 가부시키가이샤 신규 항인간 bdca-2 항체
ES2941897T3 (es) 2014-11-12 2023-05-26 Seagen Inc Compuestos que interaccionan con glicanos y procedimientos de uso
US10722592B2 (en) * 2015-03-18 2020-07-28 Seattle Genetics, Inc. CD48 antibodies and conjugates thereof
KR20240063203A (ko) * 2015-06-29 2024-05-09 이뮤노젠 아이엔씨 항-cd123 항체 및 이들의 접합체와 유도체
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
AU2016353153B2 (en) 2015-11-12 2023-11-23 Seagen Inc. Glycan-interacting compounds and methods of use
AU2016355206A1 (en) * 2015-11-19 2018-05-24 Abbvie Stemcentrx Llc Novel anti-EMR2 antibodies and methods of use
WO2017130060A1 (en) 2016-01-26 2017-08-03 Ciriello Christopher John Automated dental treatment system
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
BR112018067522A2 (pt) * 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine anticorpos específicos para receptor de poliovírus humano (pvr)
EP3426298A4 (en) * 2016-03-10 2019-11-27 Viela Bio, Inc. ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF
KR20240096672A (ko) * 2016-04-04 2024-06-26 바이오버라티브 유에스에이 인코포레이티드 항-보체 인자 bb 항체 및 이의 용도
SG11201907889YA (en) 2017-03-03 2019-09-27 Seattle Genetics Inc Glycan-interacting compounds and methods of use
CN111050792B (zh) * 2017-08-30 2024-05-31 凡恩世制药(北京)有限公司 抗lag-3抗体及其用途
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
EP3710479A2 (en) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Corp. Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
CN111542546B (zh) * 2018-01-18 2022-08-16 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
US20200017596A1 (en) * 2018-05-10 2020-01-16 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
BR112020022690A2 (pt) 2018-05-10 2021-02-09 Cyberdontics (Usa), Inc. broca dental automatizada
CA3150428A1 (en) * 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
EP4069288A4 (en) * 2019-12-06 2024-01-17 Viela Bio, Inc. TREATMENT METHODS USING ILT7 BINDING PROTEINS
IL297444A (en) 2020-04-20 2022-12-01 Genzyme Corp Humanized antibodies against complement factor bb and their use
WO2022051516A1 (en) 2020-09-03 2022-03-10 Cyberdontics (Usa), Inc. Method and apparatus for cna analysis of tooth anatomy
US20240287176A1 (en) 2021-05-04 2024-08-29 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
AR130042A1 (es) 2022-07-27 2024-10-30 Viela Bio Inc Formulaciones que comprenden una proteína de unión al transcripto 7 similar a inmunoglobulina (ilt7)
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
AU2024235162A1 (en) * 2023-03-16 2025-09-11 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
BR0108188A (pt) * 2000-02-10 2003-02-25 Abbott Lab Anticorpos que se ligam a interleucina-18 humana e métodos de produção e uso
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
DE60233674D1 (de) * 2001-10-13 2009-10-22 Asterion Ltd Glykosylphosphatidylinositolhaltige polypeptide
EP2316921B1 (en) * 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
AU2004271192B2 (en) 2003-09-03 2011-11-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
CY1116031T1 (el) 2017-01-25
BRPI0620141A2 (pt) 2011-11-01
CA2634116C (en) 2018-03-27
ME02111B (me) 2015-10-20
CA2994756A1 (en) 2007-06-28
CN103360492A (zh) 2013-10-23
CA2994756C (en) 2020-10-27
CA2634116A1 (en) 2007-06-28
RU2456298C2 (ru) 2012-07-20
US8470992B2 (en) 2013-06-25
BRPI0620141B1 (pt) 2024-04-30
KR20140053232A (ko) 2014-05-07
US20130259872A1 (en) 2013-10-03
CN110776566A (zh) 2020-02-11
IL192266A0 (en) 2008-12-29
PT1964852E (pt) 2013-07-10
RU2008129715A (ru) 2010-01-27
IL192266A (en) 2014-09-30
ES2699428T3 (es) 2019-02-11
JP2012143232A (ja) 2012-08-02
HK1124347A1 (en) 2009-07-10
CN105111311A (zh) 2015-12-02
RU2012112046A (ru) 2013-10-10
EP1964852A1 (en) 2008-09-03
SI2532681T1 (sl) 2015-03-31
CN101379089A (zh) 2009-03-04
CN101379089B (zh) 2013-08-07
CN110776566B (zh) 2025-07-15
EP2913343B1 (en) 2018-08-08
CY1121294T1 (el) 2020-05-29
US20090280128A1 (en) 2009-11-12
SG10201602095PA (en) 2016-05-30
US8084585B2 (en) 2011-12-27
NZ569910A (en) 2012-06-29
KR20080090430A (ko) 2008-10-08
EP2913343A1 (en) 2015-09-02
HK1179638A1 (en) 2013-10-04
CN120718150A (zh) 2025-09-30
US20200339682A1 (en) 2020-10-29
ES2416716T3 (es) 2013-08-02
NZ616992A (en) 2015-07-31
EP3441403A1 (en) 2019-02-13
KR20150031485A (ko) 2015-03-24
HUE039865T2 (hu) 2019-02-28
KR101585532B1 (ko) 2016-01-14
SI2913343T1 (sl) 2019-01-31
LT2913343T (lt) 2018-11-26
SG170749A1 (en) 2011-05-30
EP1964852A4 (en) 2010-02-24
ZA200805850B (en) 2009-04-29
KR101624587B1 (ko) 2016-05-26
HRP20141226T1 (hr) 2015-02-27
US20160130343A1 (en) 2016-05-12
AU2006328470A2 (en) 2008-10-09
PL2913343T3 (pl) 2019-03-29
HK1214603A1 (en) 2016-07-29
EP2532681A1 (en) 2012-12-12
AU2006328470B2 (en) 2012-08-16
RS53752B1 (sr) 2015-06-30
DK2532681T3 (en) 2015-01-05
UA97946C2 (ru) 2012-04-10
HRP20130494T1 (en) 2013-08-31
JP5020828B2 (ja) 2012-09-05
RS52860B (sr) 2013-12-31
PL2532681T3 (pl) 2015-03-31
US20120135003A1 (en) 2012-05-31
EP2532681B1 (en) 2014-10-01
RU2599450C2 (ru) 2016-10-10
MX2008007682A (es) 2008-10-23
SI1964852T1 (sl) 2013-09-30
JP5420688B2 (ja) 2014-02-19
AU2006328470A1 (en) 2007-06-28
KR101526934B1 (ko) 2015-06-26
ES2526079T3 (es) 2015-01-05
PL1964852T3 (pl) 2013-09-30
US20170204179A1 (en) 2017-07-20
JPWO2007072866A1 (ja) 2009-06-04
WO2007072866A1 (ja) 2007-06-28
PT2913343T (pt) 2018-11-21
CN105111311B (zh) 2019-10-18
DK2913343T3 (en) 2018-11-26
CY1114227T1 (el) 2016-08-31
HK1218126A1 (zh) 2017-02-03
DK1964852T3 (da) 2013-07-08
NZ599683A (en) 2013-11-29
EP1964852B1 (en) 2013-04-17
PT2532681E (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
TR201816574T4 (tr) Anti-ılt7 antikoru.
HK40004633A (en) Anti-ilt7 antibody
AU2019203877A1 (en) Anti-ilt7 antibody
HK1179638B (en) Anti-ilt7 antibody
HK1214603B (en) Anti-ilt7 antibody